🧠 What does Insulet do anyway?
Insulet $PODD (+0,88%) develops the Omnipod system - a tubeless insulin pump for diabetics.
👉 Advantage:
- No classic tube
- Easier in everyday life
- Particularly popular with younger patients
💡 The trend is clearly moving towards automated diabetes therapy (keyword: artificial pancreas)
📊 Figures that are convincing
- 📈 Sales growth: ~20-30% per year
- 💰 Turnover: over 1.5+ billion USD
- 📊 Gross margin: ~65-70%
- 🌍 Market: growing strongly worldwide (diabetes is on the rise)
👉 Important:
The addressable market is huge and growing every year
🚀 Why could the share continue to rise?
✅ More diabetes patients worldwide
✅ Trend towards modern technology (pumps instead of syringes)
✅ Recurring income (pods have to be constantly repurchased!)
✅ Strong market position in the "tubeless pumps" sector
👉 The business model is almost like a subscription model 💰
⚠️ Risks (of course there are risks)
- Competition from companies such as DexCom or Medtronic
- High valuation (not a bargain!)
- Dependence on innovation & approvals
🧭 My conclusion
👉 Insulet is not a hype play, but rather a long-term growth stock in the healthcare sector
